Maximilian J Mair is an expert in Oncology at Medical University of Vienna (Austria). Maximilian J Mair has authored 92 publications, the most recent in 2026, and is an investigator in 2 clinical trials, 1 of them ongoing. SLR score: 437 (community average: 125). How the SLR is computed.

LeadR Profile

Maximilian J Mair Medical University of Vienna Austria
437 ScienceLeadR Reputation 437
Network Map

Oncology

Subspecialties: Neurology - Nuclear Medicine

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Organizations

Career arc: 2010 - 2026

Source: PubMed

Medical University of Vienna

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 92

Citations

Citations: 1 195 1st author: 39 Last author: 0 Unique author: 0


Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
Identification of prognostically relevant residual tumor in glioblastoma after surgery: A comparative analysis of MR-based RANO resect classes vs. [18F]FET PET.
PMID 42693952 — brain neoplasms, neoplasms, tumor burden, glioblastoma
Neuro Oncol20260
PET RANO 1.0 vs. RANO 2.0 criteria for trial eligibility in IDH-wildtype glioblastoma: a retrospective, comparative study.
PMID 42599218 — brain neoplasms, glioblastoma
Neuro Oncol20260
Early radiological response pattern predicts long-term response in patients with non-small cell lung cancer treated with immune-checkpoint inhibitors.
PMID 42216080 — cells, lung, laboratories, neoplasms, carcinoma, non-small-cell lung, immune checkpoint inhibitors, lung neoplasms, small cell lung carcinoma
Cancer Imaging20260
European neuro-oncology quality assessment (ENOQUA): A European organization for the research and treatment of cancer (EORTC) brain tumor group research project.
PMID 42131752 — radiotherapy, brain neoplasms, brain, neoplasms, drug therapy, glioblastoma, research, therapeutics, chemotherapy
Neurooncol Pract20250
Lack of LAT1 and CD98hc Expression on Tumor Cells of Diffuse Glioma: Revisiting the Molecular Basis for Amino Acid PET Imaging and Theranostics.
PMID 42091177 — cells, glioma, astrocytoma, amino acids, positron-emission tomography, neoplasms, glioblastoma, oligodendroglioma, tissues
J Nucl Med20260

Clinical Studies 2

Sources: ClinicalTrials, EU CTIS

Synthesis

By phase:

N/A 1
Phase 2 1

By status:

Completed 1
Recruiting 1

By type:

Interventional 2

By Monocentric/Multicentric:

monocentric 2
multicentric2to4 0
multicentric5to9 0
multicentricup10 0

Main Topics

Ongoing Clinical Trials

Ongoing trial started since 2021, where this expert is an investigator

Source: ClinicalTrials

Study Phase Status Start
Personalized Targeted Glioblastoma Therapies by ex Vivo Drug Screening
NCT06512311 — brain neoplasms, pharmaceutical preparations, brain, neoplasms, drug evaluation, preclinical, glioblastoma, therapeutics
N/ARecruiting2024

LeadR Networks

Main global connection map